With a potential treatment for Alzheimer’s disease, a deal to co-develop a proven-effective COVID-19 vaccine for the U.S. market, and a platform of red-blood-cell-based cancer… Read More »Contraindicated: Why These 3 Biotech Stocks With Massive Gains Could Be Toxic For Portfolios
“If tech has been a rocket, small-caps have been a submarine,” analogize analysts at Jefferies, noting that “With the exception of the post-corporate tax reform… Read More »Is The Small-Cap “Submarine” Preparing To Rise?
While the emerging biotech highlighted in today’s article is still in the early stages of developing a COVID-19 vaccine, the author advises that it “has… Read More »Why This Coronavirus Stock Is Better Than Other “Pure-Play Vaccine Players”
“When you throw penny stocks and biotech stocks together…risk and volatility are magnified,” notes the author of today’s article. So, with this in mind, which… Read More »3 Biotech Penny Stocks To Watch Right Now
Shares of vaccine specialist Vaxart have exploded an astonishing 4748% so far this year, as investors have piled into the company on the hopes that… Read More »After An Incredible 4748% Surge, Still Plenty Of Room To Run For Vaxart?